Caracterização de pacientes com artrite reumatoide quanto a fatores de risco para doenças vasculares cardíacas no Mato Grosso do Sul

Deus, Ramão Souza de; Ferraz, Andressa Leite; Oesterreich, Silvia Aparecida; Schmitz, Wanderlei Onofre; Shinzato, Marcia Midori

doi:10.1016/j.rbr.2015.02.001

Cited by 4 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comorbidities in our study also were similar to those observed in other studies (Ruiz et al, 2014; Deus et al, 2015; Camargo et al, 2016; Ryan et al, 2011). Patients with RA had more cardiovascular diseases, metabolic diseases like type 2 diabetes mellitus and obesity, and muscle pain rendering in work disabilities.…”

Section: Discussionsupporting

confidence: 92%

Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting

et al. 2019

View full text Add to dashboard Cite

Background: Biological agents used for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are associated with serious adverse effects (SAEs). Although several biologics have demonstrated good efficacy and tolerability in short-term trials, treatment guidelines recommend them as third line therapies due to a relative lack of long-term safety data. Objective: To determine the frequency and severity of adverse effects associated with the long-term use of biologics in the treatment of PsA and RA, and possible risk factors for such events in a real-life setting. Methods: We conducted a longitudinal study in PsA and RA patients only taking long-term biological agents from 2003 to 2011. Sources of information included dispensing pharmacy data and interviews with patients. Research staff conducted telephone interviews with patients inquiring about any apparent medication-related adverse drug reactions (ADRs) or SAEs. ADR/SAE’s data was based on pharmacy reports. We conducted a multivariate analysis to identify the factors associated with the risk of ADRs. Results: Of the 305 patients identified, we interviewed 268 patients. Most of these were taking adalimumab 127 (47.4%), 52 (19.4%) etanercept, 42 (15.7%) infliximab, 25 (9.3%) rituximab, 10 (3.7%) abatacept, 9 (3.4%) efalizumab, and 3 (1.1%) tocilizumab. Of the 268 patients, 116 (43.3%) experienced one or more adverse events related to biological agents with 1.6 events per patient, and of these 29 (25%) experienced one or more SAEs, with majority subjected to hospitalizations. The most frequently reported ADRs were administration site reactions as observed in 73 patients (27.2%), infections in 30 patients (11.2%), effects on nervous system in 22 patients (8.2%), and 15 (5.6%) patients withdrew due to ADRs. The use of rituximab was related with less risk of ADR [PR 0.42, 95% CI 0.18–0.96; p = 0.04] than other agents. No other predisposing factors were associated with risk of ADR. The monitoring of patients (medical consultation and laboratory test) was only completed by 48 patients (30.4%). Conclusion: These data showed the early biological experience in Brazil that were associated with ADRs, withdrawals due to ADRs and SAEs. The quantification of adverse effects (serious or nonserious) considering close monitoring and patients’ perceptions are increasingly important for future decision-making.

show abstract

Section: Discussionsupporting

confidence: 92%

Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting

et al. 2019

View full text Add to dashboard Cite

show abstract

“…It is known that obesity is a frequent condition in patients with RA [31,32]. According to the present study, when we compared patients with a later diagnosis in relation to the very early, they were more strongly associated with BMI.…”

Section: Discussionmentioning

confidence: 49%

Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil

2018

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease characterized by peripheral and symmetrical polyarthritis. It can be divided into Very Early Rheumatoid Arthritis (VERA) diagnosed up to 3 months of symptoms and late onset (Late Early Rheumatoid Arthritis-LERA), diagnosed between 3 and 12 months. Currently, it is recommended to evaluate the patient with joint symptoms as early as possible, and the first 12 weeks of manifestations represent the ideal phase for the diagnosis, favoring a better evolution of the treatment. The present study aimed to determine the prevalence of early diagnosis of rheumatoid arthritis, mean time of diagnosis and to determine possible associated factors in the municipality of Blumenau, Santa Catarina, Brazil. Methods: A cross-sectional study using the 1987 American College of Rheumatology diagnostic criteria to select patients attended at primary or secondary health care units in Blumenau, Santa Catarina, southern Brazil, in 2014. Diagnostic time was verified by self-report of the time elapsed between the onset of symptoms and the diagnosis made by a rheumatologist. To test the associations, the chi-square test, the Wald linear trend test and the Poisson regression analysis were used. Results: The mean time of diagnosis was 28 months. The prevalence of diagnosis up to 3 and 12 months was 27. 7% and 64.8%, respectively. Obesity was associated with time diagnosis in both periods. The 0-4 years category of the variable education was associated only with the period up to 12 months. Conclusion: The mean time of diagnosis was similar to the national context. Among socioeconomic factors, lower education was associated with the diagnosis of late onset RA. The anthropometric variable presented a progressive increase in the prevalence due to the longer time to diagnosis.

show abstract

“…Sendo as citocinas a determinante para a gravidade e extensão dos danos teciduais (HOLLAN, 2013). Além disso, a presença de fatores de riscos coronarianos, como diabetes mellitus, hipertensão arterial, dislipidemia, índice de massa corporal e tabagismo, associados a essas doenças, acabam, muitas vezes, gerando um prognóstico ainda pior para esses pacientes reumáticos (DE DEUS et al, 2015).…”

Section: Epidemiologiaunclassified

Considerações acerca de Cardiopatias de Doenças Reumáticas

et al. 2023

View full text Add to dashboard Cite

Várias doenças reumáticas autoimunes (DRA) são responsáveis pelo aumento do risco de comorbidades cardiovasculares, seja por aterosclerose, formação de trombos, vasculite ou inflamação miocárdica. O aprimoramento de práticas terapêuticas e o aumento da expectativa de vida dos pacientes trouxe um novo olhar para as complicações cardiovasculares decorrentes de desordens reumatológicas. O presente artigo tece considerações acerca de cardiopatias nas Doenças Reumáticas. Os resultados demonstraram ser a atividade física uma das intervenções comportamentais mais importantes, como um impacto benéfico na probabilidade de se desenvolver, sofrer sintomaticamente ou morrer de DCV. Dessa forma, manter um estilo de vida saudável reduz os fatores de risco para DCV, incluindo a obesidade, dislipidemia, hipertensão, diabetes mellitus e possivelmente até inflamação. Também mostrou eficácia na prevenção de síndromes coronarianas agudas. O exercício parece ajudar no manejo das DCV estabelecidas, seja ele exercício aeróbico ou o treinamento resistido. Melhoram a contratilidade miocárdica e a qualidade de vida em pacientes com insuficiência cardíaca crônica.

show abstract

Caracterização de pacientes com artrite reumatoide quanto a fatores de risco para doenças vasculares cardíacas no Mato Grosso do Sul

Abstract: An association of increased TC and triglycerides with results of HAQ ≤ 1 and with CS use was noted, reinforcing the importance of screening risk factors associated with cardiovascular disease in RA.

Cited by 4 publications

References 36 publications

Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting

Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting

Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil

Considerações acerca de Cardiopatias de Doenças Reumáticas

Contact Info

Product

Resources

About